Conditions: Advanced Solid Tumors
Keywords: Solid Tumors Transforming Growth Factor Beta Activin Receptor-like Kinase 1
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 70
Healthy volunteers: no

Brief summary:
The purpose of this study is to test the safety and effectiveness of PF-03446962 when given as a single agent. Tumors require new blood vessels to support their ability to grow and to spread (metastasize). New treatments aimed at preventing these blood vessels have the ability to improve the clinical management of cancer.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: PF-03446962
Intervention descriptions: intervention 1: To determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of PF-03446962 administered in patients with advanced solid tumors.

Protocol document: